Print

HVTN 702

NCT02968849

Trial Details:

III Ongoing
NIH, HVTN, South African Medical Research Council, Pox-Protein Public-Private Partnership, GSK, Sanofi, BMGF
ALVAC-HIV-C (vCP2438), Bivalent Subtype C gp120/MF59
Healthy adults
RandD/trials/Lists/ClinicalTrialsList
7/1/2021
Canarypox Env gp120 C, gp41 B, gag B, protease B; Protein Env C
? IM injection of ALVAC-HIV  at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12